The ability to identify Duchenne-affected newborns within the first few weeks of life will empower parents to enroll their children in suitable clinical trials and start treatment as early as possible. It will also help the community to better understand the incidence of Duchenne and learn more about early symptoms of the disease. Additionally, access to this kind of screening can provide a clearer understanding of phenotype and genotype linking that will benefit a much larger population, according to a media release from CureDuchenne.
“Newborn screening allows for early diagnosis, which is incredibly beneficial for patients and their families to initiate treatment as soon as clinically recommended. This can lead to better health outcomes for patients and avoidance of lengthy diagnostic odysseys, which delay crucial treatment,” says Debra Miller, founder and CEO of CureDuchenne, in the release.
Richard West, co-founder and CEO of Baebies, comments that, “It is partnerships with organizations like CureDuchenne that will help us make the greatest possible impact. With a shared mission, this partnership will enable us to find these babies when they’re born and get them started on the treatment they need as soon as possible.”
[Source(s): CureDuchenne, Business Wire]